Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ: PMN )

1.030 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 Next >
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease
Rationally Designed PMN310 Targets Toxic Amyloid-Beta Oligomers Selectively and Efficiently ProMIS Neurosciences, a pioneering biotech firm specializing in antibody therapeutics 
Via Spotlight Growth
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.